<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624074</url>
  </required_header>
  <id_info>
    <org_study_id>1R01MH120550-01A1</org_study_id>
    <nct_id>NCT04624074</nct_id>
  </id_info>
  <brief_title>TMCU for Young Adults With FEP</brief_title>
  <official_title>Pilot Testing a TMCU Adapted for Young Adults With First Episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to pilot test an adapted version of the Teen Marijuana Check Up (TMCU) for&#xD;
      persistent cannabis users with first episode psychosis (FEP) in Coordinated Specialty Care&#xD;
      (CSC). The adapted version of the TMCU will include tailoring to risks of persistent cannabis&#xD;
      use in FEP, providing education on lower risk cannabis use, and adding a session to address&#xD;
      collaborative planning to maintain CSC engagement and antipsychotic adherence and to reduce&#xD;
      harm associated with cannabis use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timeline Followback</measure>
    <time_frame>baseline, immediately after the intervention</time_frame>
    <description>Change in cannabis use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Colorado Symptom Index</measure>
    <time_frame>baseline, immediately after the intervention</time_frame>
    <description>Change in psychosis symptoms</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>Teen Marijuana Checkup - adapted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Teen Marijuana Check Up</intervention_name>
    <description>Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.</description>
    <arm_group_label>Teen Marijuana Checkup - adapted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 13-35&#xD;
&#xD;
          2. DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder,&#xD;
             brief psychotic disorder, delusional disorder, other specified schizophrenia spectrum&#xD;
             and other psychotic disorder, and unspecified schizophrenia spectrum and other&#xD;
             psychotic disorder&#xD;
&#xD;
          3. Duration of illness: â‰¤ 2 years&#xD;
&#xD;
          4. Enrolled at a Coordinated Specialty Care program&#xD;
&#xD;
          5. Report current use of cannabis&#xD;
&#xD;
          6. Ability and willingness to provide informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Individuals who do not meet all inclusion criteria are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melanie Bennett, PhD</last_name>
    <phone>410-706-0892</phone>
    <email>mbennett@som.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Taylor</last_name>
    <email>jktaylor@som.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Bennett</last_name>
      <phone>410-706-0892</phone>
      <email>mbennett@som.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Melanie Bennett</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

